Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround

Core Viewpoint - AN2 Therapeutics, Inc. (ANTX) has experienced a downtrend with a 5.5% decline over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Stock Performance and Indicators - The stock has been under significant selling pressure, indicated by an RSI reading of 24.66, which suggests it is oversold [4]. - A stock is generally considered oversold when its RSI falls below 30, and ANTX's current RSI indicates a potential reversal in trend [2]. Group 2: Earnings Estimates and Analyst Consensus - Over the last 30 days, the consensus EPS estimate for ANTX has increased by 4.1%, reflecting a strong agreement among analysts regarding improved earnings [4]. - ANTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a favorable outlook for a turnaround [5].